glp 1 oral fda approved US accepts Novo Nordisk's application for Wegovy for weight loss Founday (orforglipron), the new oral

The presentation emphasized that weight loss is not synonymous with health , and that protecting eating disorder recovery requires intentional, informed, and weight-inclusive clinical practice

Koniver greeted me in his waiting room, which featured a soft-rock soundtrack and brochures for serums and stem cells

This is a common concern for patients considering GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)

Below are some takeaways that help contextualize what FDA appears to be prioritizingand what stakeholders should expect going forward

Mechanism of Action: GLP-1 receptor agonists work through multiple physiological pathways: Central appetite suppression : These medications cross the blood-brain barrier and activate GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals and increasing satiety Gastric emptying delay : By slowing stomach emptying, patients experience prolonged fullness after meals Insulin secretion enhancement : Glucose-dependent insulin release improves glycemic control Glucagon suppression : Reduced glucagon secretion decreases hepatic glucose production Tirzepatide offers dual agonism at both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, potentially providing enhanced weight loss efficacy compared to single-agonist medications